ArticleMolecular biology reports2025
Novel heterozygous mutation in KMT2B causing an unusual phenotypic presentation: a comprehensive clinical and bioinformatic analysis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Central precocious puberty as the initial manifestation of multisystem involvement caused byFrontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKMT2B-related dystonia is a childhood-onset movement disorder. This study investigated a novel KMT2B gene variant using whole exome sequencing (WES) and bioinformatics analysis, and expanded the known clinical spectrum of KMT2B-related dystonia by characterizing an atypical dystonic pattern.
methodsA pediatric neurologist performed a comprehensive clinical evaluation of a 13-year-old girl who presented with left leg and right-hand spasms (cross-dystonia), which resulted in gait and writing difficulties over the past two years. The evaluation was complemented by brain magnetic resonance imaging and detailed neuro-metabolic testing. Genomic DNA underwent WES, and the newly identified variant was validated through Sanger sequencing, followed by trio analysis in the family. Various in silico prediction tools were used to assess the mutation's pathogenicity. Bioinformatics tools, including SMART, PROSITE, CDD, COACH, and COFACTOR, -were employed to provide a thorough analysis of the structural and functional characteristics associated with this mutation.
resultsMolecular investigations through WES analysis revealed a novel pathogenic variant: a heterozygous G→T nonsense mutation at position 1363 in exon 3 of the KMT2B gene (NM_014727.3) (c.1363G > T), predicting pathogenic amino acid change to a premature stop codon (NP_055542: p.E455X). Bioinformatic analysis using the SEG program showed that the mutation was located in a low compositional complexity region spanning residues 392-463. Predictions from SVM, neural networks, and sequence information indicated both the changes in energy values and sign of energy change, showing decreased stability in the mutated protein structure.
conclusionThis newly identified KMT2B mutation with an unusual clinical phenotype highlighted its regulatory role and underscored the connection between protein structure, function, and disease manifestation.
Indexed as
Identifiers
41222778What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.